Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
| 3.92 | |
| 3.9 | |
| - | |
| 3.97 | |
| 3.78 | |
| 2.765-4.6 | |
| 328 M | |
| 84 223 K | |
| 192 M | |
| -0.75 | |
| 0.176 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Atea Pharmaceuticals, Inc. AVIR, a clinical-stage company, reported positive initial data from the first 52 patients in the lead-in cohort of the mid-stage study evaluating its bemnifosbuvir and ruza...
Atea Pharmaceuticals, Inc. A 98% Sustained Virologic Response at Week 4 (SVR4) Post-Treatment Observed in Initial Data From 52 Patients in Lead-In Cohort in Phase 2 HCV Study Phase 3 SUNRISE-3 Enrol...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
